Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies

Abstract

Amer Zeidan speaks to Laura Dormer, Editorial Director: Amer Zeidan is Assistant Professor of Medicine (Hematology) at Yale Cancer Center. He completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science degree in Clinical Investigation. He received his MBBS degree from the Faculty of Medicine, University of Jordan (Amman, Jordan), before completing his internal medicine residency at Rochester General Hospital (USA). His clinical interest is in the management of hematologic malignancies. The focus of his clinical/translational research is the development of novel therapies for MDS and myeloid hematologic malignancies. The second area of research interest for him is effectiveness and outcomes research in hematologic malignancies, especially MDS.